- Home
- CUE vs ORMP Comparison
CUE vs ORMP Comparison
Compare CUE & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | ORMP |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 104.6M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CUE | ORMP |
|---|---|---|
| Price | $0.25 | $2.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 545.8K | 226.4K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 838.25 |
| EPS | N/A | ★ 1.03 |
| Revenue | ★ $7,100,000.00 | $2,000,000.00 |
| Revenue This Year | $36.58 | N/A |
| Revenue Next Year | $32.10 | N/A |
| P/E Ratio | ★ N/A | $2.85 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $1.82 |
| 52 Week High | $1.75 | $3.20 |
Technical Indicators
Market Signals| Indicator | CUE | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 14.00 | 63.49 |
| Support Level | $0.47 | $2.83 |
| Resistance Level | $0.51 | $3.19 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 3.67 | 61.12 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.